Rachel Eisenberger
Acute Care · Myrtle Beach, SCNPI 1356939862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AstraZeneca at 30.9% of the total. Among acute care clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$792
- Sanofi$538
- Regeneron Healthcare Solutions, Inc.$461
- Insmed, Inc.$288
- United Therapeutics Corporation$223
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,52695%
- Education$2695%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 77 | $1,791 |
| GSK | 46 | $792 |
| Sanofi | 17 | $538 |
| Regeneron Healthcare Solutions, Inc. | 14 | $461 |
| Insmed, Inc. | 10 | $288 |
| United Therapeutics Corporation | 8 | $223 |
| Merck | 10 | $195 |
| Sanofi-aventis U.S. LLC | 2 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $158 |
| Boehringer Ingelheim | 6 | $146 |
| Amgen | 7 | $141 |
| Verona Pharma, Inc. | 5 | $114 |
| Actelion Pharmaceuticals US, Inc. | 5 | $98 |
| Vifor Pharma, Inc. | 4 | $92 |
| Novartis | 4 | $89 |
| Viatris Specialty LLC | 5 | $83 |
| Paratek Pharmaceuticals, Inc. | 4 | $72 |
| Baxter Healthcare | 3 | $71 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| CSL Behring | 1 | $27 |
| Genentech USA, Inc. | 1 | $25 |
| Pfizer | 1 | $25 |
| Grifols USA, LLC | 1 | $21 |
| AbbVie | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Electromed, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,795 in reported general payments places this provider in the 90th percentile of 339 acute care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 296 | $257,157 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 85 | $73,941 |
| NucalaMepolizumab | 14 | $51,644 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $26,706 |
| Spiriva RespimatTiotropium Bromide | 15 | $12,164 |
| Spiriva HandihalerTiotropium Bromide | 20 | $10,191 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $9,283 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 313 | $9,244 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $7,557 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $6,304 |
| Arnuity ElliptaFluticasone Furoate | 18 | $6,173 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,067 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,509 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,549 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $3,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $792 | $353,493412 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,791 | $80,008102 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $146 | $21,44734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 acute care providers in South Carolina.
Other acute care in Myrtle Beach
- Laura SeiptMyrtle Beach$8K
- Heather BowersGreenville$94K
- Michael GajewskiColumbia$62K
- Heather NortonMt Pleasant$57K
- Cameron ThomassonSumter$28K
- Sarah MatthewsGreenville$28K
- Micheal BungerColumbia$15K
- Robin TrauflerColumbia$12K
- Susan FunkGreenville$11K
- Linda HentzLexington$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.